Miniaturization and Automation of Tissue Chip Systems (MATChS) (UT1/UT2 - Clinical Trial Not Allowed)
ID: 351095Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351095

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-018.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Miniaturization and Automation of Tissue Chip Systems (MATChS)" aimed at U.S. small business concerns through STTR Phase I and II cooperative agreements. The initiative seeks to develop innovative microphysiological systems (MPS) that replicate human organ functions for drug discovery and biomedical research, addressing the limitations of traditional methods that are often costly and time-consuming. This funding opportunity is crucial for advancing tissue chip technology, enhancing the accessibility and usability of these systems in research, and supporting safe therapeutic assessments. Interested applicants can apply for a total funding commitment of up to $2.15 million, with key submission dates including an open date for applications on January 22, 2024, and a closing date of February 23, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-018.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-TR-23-018-Full-Announcement.html
    RFA-TR-23-018.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces the Miniaturization and Automation of Tissue Chip Systems (MATChS) funding opportunity. This initiative invites U.S. small business concerns to submit applications for STTR Phase I and II cooperative agreements. The MATChS aims to develop innovative microphysiological systems (MPS) that mimic human organ functions for drug discovery and biomedical research, addressing challenges in traditional methods that are costly and time-consuming. Objectives include creating portable and automated MPS platforms with integrated sensors for high-throughput data analysis. The initiative builds upon previous collaborations between NIH, NCATS, and NASA, enhancing accessibility and usability of tissue chips in research. Key dates include an open date for submissions on January 22, 2024, and a funding commitment of up to $2.15 million for two Phase I awards and one Phase II award in FY 2024. The announcement emphasizes the need for milestone-driven projects with active NIH involvement in their development. Eligible applicants must be organized for profit, have a significant U.S. presence, and meet specific ownership and employee criteria. The MATChS serves to further the field of tissue chip technology, supporting safe and efficient therapeutic assessments while driving towards commercialization and practical application in clinical settings.
    Similar Opportunities
    Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Miniaturization and Automation of Tissue Chip Systems" (MATChS), aimed at advancing the development of automated and miniaturized microphysiological systems (MPS) for drug discovery and biomedical research. This funding opportunity encourages U.S. small business concerns (SBCs) to propose innovative solutions that enhance the efficiency and reliability of tissue chip technologies, with a focus on reducing complexity and costs while facilitating higher throughput. Approximately $2.15 million is allocated for FY 2024 to support projects that collaborate with NIH staff to achieve defined milestones and pathways to commercialization. Interested applicants must submit their proposals by February 23, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Intramural - Extramural Collaboration for Advanced 3-D Tissue Models for Drug Screening (Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Intramural - Extramural Collaboration for Advanced 3-D Tissue Models for Drug Screening," aimed at developing and validating advanced 3-D tissue models for drug efficacy testing. This initiative seeks to create non-animal models that accurately mimic the physiological properties of human tissues, thereby enhancing the predictive accuracy of drug screening processes. With an estimated total program funding of $1,600,000 and the expectation of awarding two grants, interested applicants are encouraged to utilize the resources available at the NCATS 3-D Bioprinting laboratory. The application process is open to various eligible entities, excluding non-domestic applicants, with a submission deadline anticipated by June 16, 2026. For further inquiries, potential applicants can contact Dobrila D. Rudnicki, Ph.D., at dobrila.rudnicki@nih.gov or by phone at 240-535-6621.
    Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies (U01 Clinical Trial Not Allowed)" aimed at advancing research in regenerative medicine utilizing adult stem cells. This initiative, supported by the 21st Century Cures Act, encourages small businesses to develop collaborative projects that contribute to the field, although applications are not currently being solicited. With an estimated total program funding of $400,000, interested applicants should prepare for the upcoming Notice of Funding Opportunity (NOFO), with key dates including an estimated synopsis post date of August 1, 2025, and a close date of October 21, 2025. For further inquiries, potential applicants can contact Aron Marquitz, Ph.D., at aron.marquitz@nih.gov or by phone at 301-435-1240.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)," aimed at encouraging exploratory research to develop advanced microphysiological systems (MPS) that accurately replicate complex human nervous system architectures. This initiative seeks to facilitate studies on nervous system development, function, and aging, particularly in relation to neurological diseases. The R21 grant allows for a budget of up to $275,000 over two years, with applications opening on January 16, 2025, and a submission deadline of January 7, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator- Initiated Studies (UH3 Clincical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies," aimed at advancing research in regenerative medicine utilizing adult stem cells. This initiative, supported by the 21st Century Cures Act, encourages small businesses to develop collaborative projects, although applications are not currently being solicited. The funding will be provided through a cooperative agreement, with an estimated synopsis posting date of August 1, 2025, and a closing date for applications expected by October 21, 2025. For further inquiries, interested parties can contact Aron Marquitz, Ph.D., at aron.marquitz@nih.gov or by phone at 301-435-1240.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 grant mechanism to support the development of next-generation human cell-derived microphysiological systems (MPS) that accurately replicate the architectures and functions of the human nervous system. This initiative aims to encourage high-risk, high-reward exploratory research, particularly relevant for addressing complex nervous system disorders, and is open to a diverse range of eligible applicants, including educational institutions, non-profits, and governmental entities. The funding, capped at $275,000 over a two-year period, emphasizes collaboration among experts in neurobiology, engineering, and ethics, and applications must adhere to NIH data management and sharing policies. Interested parties can find more information and submit inquiries via grantsinfo@nih.gov, with the application deadline set for January 7, 2026.
    Resource-Related Research Projects for Development of Models and Related Materials for Studying Human Health and Diseases (R24 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Resource-Related Research Projects for Development of Models and Related Materials for Studying Human Health and Diseases (R24 Clinical Trials Not Allowed)." This funding aims to support small businesses in developing, characterizing, or improving research models related to human health and diseases, as well as creating new approach methodologies (NAMs) that enhance the accessibility and translational value of experimental research models. The initiative is crucial for advancing biomedical research and ensuring that developed resources are broadly applicable across multiple NIH Institutes or Centers. The estimated total program funding is $5 million, with approximately six awards expected. Interested applicants should prepare to submit their proposals by January 25, 2026, with the anticipated award date set for October 1, 2026. For further inquiries, contact Sige Zou, PhD, at 301-435-0749 or via email at sige.zou@nih.gov.
    PHS 2025-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting eligible United States small business concerns (SBCs) to prepare applications for the PHS 2025-2 Omnibus Solicitation for Small Business Technology Transfer (STTR) Grant Applications, which includes Phase I, Phase II, Fast-Track, and Phase IIB grants. This opportunity aims to support innovative research and development projects that align with the NIH's mission, encouraging collaborations that leverage the technological expertise of small businesses in the health sector. The solicitation is contingent upon the reauthorization of the STTR program, with an estimated synopsis posting date of October 1, 2025, and a closing date of January 5, 2026. Interested applicants can reach out to the NIH SEED Office of Extramural Research at SEEDinfo@nih.gov or call 301-827-8595 for further information.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)," aimed at advancing research in human cell-derived microphysiological systems (MPS) that replicate complex nervous system architectures and functions. This initiative seeks innovative applications that address technological barriers in studying nervous system development and diseases, with a focus on improving physiological relevance and circuit-level activity in existing assays. The funding is open to a wide range of eligible applicants, including higher education institutions and non-profits, with a project period of up to five years and no cost-sharing requirement. Interested parties should note that the application deadline is January 7, 2026, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the announcement page at https://grants.nih.gov/grants/guide/pa-files/PAR-23-046.html.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) aimed at advancing research in the development of next-generation human cell-derived microphysiological systems (MPS) that accurately replicate complex nervous system physiology. This funding opportunity, under the R01 Research Project Grant mechanism, encourages innovative applications that focus on enhancing existing technologies and creating sophisticated models for studying the nervous system's development, function, and aging, while explicitly excluding clinical trial projects. Eligible applicants include a diverse range of organizations, such as educational institutions and community-based organizations, with no specific budget limits as long as costs align with the proposed research. Interested parties should note that the application submission period opens on January 3, 2025, with a closing date of January 7, 2026, and are encouraged to contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.